Immunotherapy for Melanoma Info Update
On July 30,
2020, the U.S. FDA approved atezolizumab (Tecentriq) in combination with MEK and
BRAF inhibitors for the treatment of patients with BRAF V600 mutation-positive
advanced melanoma. As the research and treatment landscape evolves, we keep our
information up to date.
No comments:
Post a Comment